PD60-11 HYPOGONADISM PREDICTS HOSPITAL ADMISSION IN MEN WITH COVID-19 INFECTION

You have accessJournal of UrologyHealth Services Research: Practice Patterns, Quality of Life and Shared Decision Making V (PD60)1 Sep 2021PD60-11 HYPOGONADISM PREDICTS HOSPITAL ADMISSION IN MEN WITH COVID-19 INFECTION Mahdi Bazzi, Irene Chen, Guillame Farah, Jacob Keeley, Firas Abdollah, Ali Dabaja, and Amarnath Rambhatla Mahdi BazziMahdi Bazzi , Irene ChenIrene Chen , Guillame FarahGuillame Farah , Jacob KeeleyJacob Keeley , Firas AbdollahFiras Abdollah , Ali DabajaAli Dabaja , and Amarnath RambhatlaAmarnath Rambhatla View All Author Informationhttps://doi.org/10.1097/JU.0000000000002097.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The coronavirus disease 2019 (COVID-19) pandemic continues to be a global health crisis despite the recent worldwide vaccine distribution. The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is most commonly believed to cause severe disease manifestations secondary to a cytokine storm. Low testosterone is associated with a pro-inflammatory environment and it is thought that a eugonadal testosterone level may be protective of increased cytokine activity. Objective: In this study, we explore the association between baseline testosterone level and COVID-19 clinical outcomes. METHODS: Through a retrospective chart review, we identified 188 males from an academic health system in a metropolitan area diagnosed with COVID-19 with measured baseline testosterone levels who were not on testosterone replacement therapy. The 188 males were divided into eugonadal (n=90, >300 ng/dL) and hypogonadal (n=98, ≤300 ng/dL) testosterone groups. Data regarding comorbidities and endpoints such as hospital admission, intensive care unit admission, ventilator utilization, and thromboembolic events were extracted. Chi-square and Fisher's Exact tests examined differences in categorical variables. Logistic regression analysis tested the relationship between testosterone level and endpoints. RESULTS: There were 188 men identified who met our inclusion criteria. There were 90 men in the eugonadal group and 98 men in the hypogonadal group. Median age (IQR) was 55 (43-67) for the eugonadal group and 55 (40-63) for the hypogonadal group, median BMI was 30.6 (27.7-35.4) and 31.3 (26.4-35.6), and median testosterone level was 396 (357-476.3 ng/dL) and 217 (141.3 – 255 ng/dL) for the two groups respectively. Hypogonadism was significantly related to hospital admission (p=0.027). While not statistically significant, there were more ICU admissions (p=0.75), ventilator use (p=0.75), and DVTs seen in the hypogonadal group. On logistic regression analysis, hypogonadism was predictive of hospital admission (p=0.021). CONCLUSIONS: Eugonadal testosterone level may be protective of more severe clinical outcomes in COVID-19. Hypogonadism is associated with increased hospital admission. Further research with a larger sample size needs to be conducted to fully understand the relationship between testosterone and clinical outcomes in COVID-19. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e1064-e1065 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.Metrics Author Information Mahdi Bazzi More articles by this author Irene Chen More articles by this author Guillame Farah More articles by this author Jacob Keeley More articles by this author Firas Abdollah More articles by this author Ali Dabaja More articles by this author Amarnath Rambhatla More articles by this author Expand All Advertisement PDF downloadLoading ...